[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event
On August 12, 2025, Lineage Cell Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is provided as Exhibit 99.1. The Form 8-K states the information is being furnished, not filed, and therefore is not incorporated by reference into other filings. The filing also includes an Inline XBRL cover page as Exhibit 104. The report is signed by George A. Samuel III, General Counsel and Corporate Secretary.
Il 12 agosto 2025 Lineage Cell Therapeutics ha diffuso un comunicato stampa con i risultati finanziari per il trimestre chiuso al 30 giugno 2025, fornito come Exhibit 99.1. Il Form 8-K indica che l'informazione 猫 fornita, non depositata, e pertanto non viene incorporata per riferimento in altri documenti. La comunicazione include inoltre una pagina di copertina Inline XBRL come Exhibit 104. Il rapporto 猫 firmato da George A. Samuel III, Direttore legale e Segretario societario.
El 12 de agosto de 2025 Lineage Cell Therapeutics public贸 un comunicado de prensa con sus resultados financieros correspondientes al trimestre terminado el 30 de junio de 2025, proporcionado como Exhibit 99.1. El Formulario 8-K indica que la informaci贸n se est谩 proporcionando, no presentando, y por tanto no se incorpora por referencia en otros documentos. La presentaci贸n tambi茅n incluye una portada Inline XBRL como Exhibit 104. El informe est谩 firmado por George A. Samuel III, asesor jur铆dico principal y secretario corporativo.
2025雲� 8鞗� 12鞚� Lineage Cell Therapeutics電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頄堨溂氅�, 頃措嫻 鞛愲電� Exhibit 99.1搿� 鞝滉车霅橃棃鞀惦媹雼�. Form 8-K電� 頃措嫻 鞝曤炒臧� 鞝滉车霅� 瓴冹澊氅� 鞝滌稖霅� 瓴冹潃 鞎勲嫎鞚措澕瓿� 氇呾嫓頃橃棳 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婋姅雼り碃 氚濏様鞀惦媹雼�. 鞝滌稖氍检棎電� 霕愴暅 Exhibit 104搿� Inline XBRL 響滌 韼橃澊歆�臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滊姅 George A. Samuel III 氩曤齑濌磩(General Counsel) 瓴� 須岇偓 靹滉赴鞚� 靹滊獏鞙茧 鞝滌稖霅橃棃鞀惦媹雼�.
Le 12 ao没t 2025, Lineage Cell Therapeutics a diffus茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025, fourni en tant que Exhibit 99.1. Le formulaire 8-K pr茅cise que l'information est fournie, non d茅pos茅e, et n'est donc pas incorpor茅e par renvoi dans d'autres documents. Le d茅p么t comprend 茅galement une page de garde Inline XBRL en tant que Exhibit 104. Le rapport est sign茅 par George A. Samuel III, conseiller juridique principal et secr茅taire de la soci茅t茅.
Am 12. August 2025 ver枚ffentlichte Lineage Cell Therapeutics eine Pressemitteilung mit den Finanzergebnissen f眉r das Quartal zum 30. Juni 2025, die als Exhibit 99.1 beigef眉gt ist. Das Form 8-K weist darauf hin, dass die Informationen bereitgestellt, nicht eingereicht werden und daher nicht durch Verweis in andere Einreichungen aufgenommen werden. Die Einreichung enth盲lt au脽erdem eine Inline-XBRL-Titelseite als Exhibit 104. Der Bericht ist unterschrieben von George A. Samuel III, leitender Rechtsberater und Unternehmenssekret盲r.
- None.
- None.
Insights
TL;DR Routine 8-K furnishing Q2 results; substantive figures reside in the press release, not the form鈥攍imited immediate impact.
The filing notifies investors that a press release reporting financial results for the quarter ended June 30, 2025 was furnished as Exhibit 99.1. This Form 8-K does not itself contain financial figures or analysis; it functions as a procedural disclosure that points investors to the press release. Because the information is expressly "furnished, not filed," it is not incorporated by reference into other filings. Review of Exhibit 99.1 is required to assess revenue, earnings, cash position, or other material financial metrics.
TL;DR The 8-K follows standard disclosure practice, clarifying furnished status and including the required exhibits and signature.
This submission reflects routine compliance: it lists Exhibits 99.1 (press release) and 104 (Inline XBRL cover page), and includes the registrant's signature by the General Counsel and Corporate Secretary. The explicit statement that the information is furnished and not incorporated by reference is a legal distinction that limits automatic reuse of the press release content in future filings. There are no governance red flags or executive changes disclosed in this document.
Il 12 agosto 2025 Lineage Cell Therapeutics ha diffuso un comunicato stampa con i risultati finanziari per il trimestre chiuso al 30 giugno 2025, fornito come Exhibit 99.1. Il Form 8-K indica che l'informazione 猫 fornita, non depositata, e pertanto non viene incorporata per riferimento in altri documenti. La comunicazione include inoltre una pagina di copertina Inline XBRL come Exhibit 104. Il rapporto 猫 firmato da George A. Samuel III, Direttore legale e Segretario societario.
El 12 de agosto de 2025 Lineage Cell Therapeutics public贸 un comunicado de prensa con sus resultados financieros correspondientes al trimestre terminado el 30 de junio de 2025, proporcionado como Exhibit 99.1. El Formulario 8-K indica que la informaci贸n se est谩 proporcionando, no presentando, y por tanto no se incorpora por referencia en otros documentos. La presentaci贸n tambi茅n incluye una portada Inline XBRL como Exhibit 104. El informe est谩 firmado por George A. Samuel III, asesor jur铆dico principal y secretario corporativo.
2025雲� 8鞗� 12鞚� Lineage Cell Therapeutics電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頄堨溂氅�, 頃措嫻 鞛愲電� Exhibit 99.1搿� 鞝滉车霅橃棃鞀惦媹雼�. Form 8-K電� 頃措嫻 鞝曤炒臧� 鞝滉车霅� 瓴冹澊氅� 鞝滌稖霅� 瓴冹潃 鞎勲嫎鞚措澕瓿� 氇呾嫓頃橃棳 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婋姅雼り碃 氚濏様鞀惦媹雼�. 鞝滌稖氍检棎電� 霕愴暅 Exhibit 104搿� Inline XBRL 響滌 韼橃澊歆�臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滊姅 George A. Samuel III 氩曤齑濌磩(General Counsel) 瓴� 須岇偓 靹滉赴鞚� 靹滊獏鞙茧 鞝滌稖霅橃棃鞀惦媹雼�.
Le 12 ao没t 2025, Lineage Cell Therapeutics a diffus茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025, fourni en tant que Exhibit 99.1. Le formulaire 8-K pr茅cise que l'information est fournie, non d茅pos茅e, et n'est donc pas incorpor茅e par renvoi dans d'autres documents. Le d茅p么t comprend 茅galement une page de garde Inline XBRL en tant que Exhibit 104. Le rapport est sign茅 par George A. Samuel III, conseiller juridique principal et secr茅taire de la soci茅t茅.
Am 12. August 2025 ver枚ffentlichte Lineage Cell Therapeutics eine Pressemitteilung mit den Finanzergebnissen f眉r das Quartal zum 30. Juni 2025, die als Exhibit 99.1 beigef眉gt ist. Das Form 8-K weist darauf hin, dass die Informationen bereitgestellt, nicht eingereicht werden und daher nicht durch Verweis in andere Einreichungen aufgenommen werden. Die Einreichung enth盲lt au脽erdem eine Inline-XBRL-Titelseite als Exhibit 104. Der Bericht ist unterschrieben von George A. Samuel III, leitender Rechtsberater und Unternehmenssekret盲r.
FAQ
What did Lineage Cell Therapeutics (LCTX) report in this 8-K?
Where can I find the financial details for LCTX's quarter ended June 30, 2025?
Is the press release incorporated by reference into other filings?
What exhibits were included with this Form 8-K?
When was this Form 8-K filed?
What is Lineage Cell Therapeutics' trading symbol and exchange?
